Heuking Kühn Lüer Wojtek accompanied Deutsche Biotech Innovative AG (DBI AG) on performing a capital increase with shareholder subscription rights and on its IPO. A team led by Munich-based partner Boris Dürr advised the company listed on Düsseldorf Stock Exchange's Primary Market in particular on drafting the relevant securities prospectus. The IPO includes 596,400 shares offered at a subscription price of EUR 33.50. The company therefore aims to raise proceeds of some EUR 20 million. Following the capital increase, listing of the shares at Frankfurt Stock Exchange's Entry Standard is also planned.
Deutsche Biotech Innovativ AG is a biotechnology holding company researching innovative therapies for serious diseases and subsequently developing corresponding drug candidates through individual project companies. Greatest hope is currently placed in the patented active ingredient Adrecizumab, a new drug to reduce mortality by organ failure in septic shock. Although per year some 8 million people die from it, there is currently no drug approved worldwide. Adrecizumab has successfully passed the preclinical phase and will be tested in a Phase I trial as of the end of 2015.
DBI AG intends to use the proceeds from the capital increase to continue funding the preclinical and clinical development of its currently three drug candidates, particularly in the indications of sepsis and cancer, including the aforementioned drug Adrecizumab, as well as a diagnostic agent for the early detection of urinary tract infections. DBI AG's business model provides for a sale or licensing of active ingredients during clinical development, classically during or after a phase II trial.
Based on the budget, in case of full placement of the capital increase, the funds will last until the first sale of an agent and thus until the first proceeds from the product pipeline. This first exit is expected to be realized by 2018/2019.
Counsel to Deutsche Biotech Innovativ AG
Heuking Kühn Lüer Wojtek:
Boris Dürr (Lead)
Ricarda Marschall (both Capital Market Law, Munich)